GKSL Submits Q2 FY27 Investor Presentation, Highlights Strong YoY Growth
Gujarat Kidney And Super Speciality Limited (GKSL) released its Q2 FY27 investor presentation. The company reported strong YoY growth with Q2 FY27 revenue at ₹3,809 Lakhs (+195% YoY), EBITDA at ₹1,022 Lakhs (+99% YoY), and PAT at ₹660 Lakhs (+129% YoY). H1 FY27 revenue reached ₹7,238 Lakhs (+157% YoY). The presentation also detailed inorganic expansion and operational improvements.
The investor presentation provides comprehensive financial and strategic updates, including significant growth figures and future plans, which are crucial for investors and stakeholders.
The announcement highlights significant year-on-year growth in revenue, EBITDA, and PAT, indicating strong financial performance and positive business momentum.
Gujarat Kidney And Super Speciality Limited (GKSL) has submitted its investor presentation for the second quarter of the financial year 2027. The presentation, available on the company's website and disclosed to BSE and NSE, details significant year-on-year growth in key financial metrics.
For Q2 FY27, GKSL reported revenue from operations of ₹3,809 Lakhs, marking a substantial increase of 195% year-on-year. EBITDA stood at ₹1,022 Lakhs with a margin of 26.8%, showing a 99% YoY growth. Profit After Tax (PAT) for the quarter was ₹660 Lakhs, a 129% increase YoY. The company also highlighted strong performance for the first half of FY27 (H1 FY27), with revenue from operations reaching ₹7,238 Lakhs, up 157% YoY, and PAT at ₹1,192 Lakhs, a 44% increase YoY.
The presentation also provides insights into the company's strategic initiatives, including inorganic expansion with ₹1,669 lakhs deployed towards acquisitions in H1 FY27, and operating leverage leading to margin expansion. Clinical volumes are scaling up, with H1 FY27 showing 11,040 IPD admissions and 78,643 OPD visits. The company maintains a strong, net-cash balance sheet with a net worth of ₹26,364 Lakhs and net cash of ₹1,488 Lakhs.
Furthermore, GKSL's presentation touches upon its integrated business model, asset-light expansion, and expansion beyond Gujarat through a Dubai healthcare platform. The company is also exploring strategic inorganic growth opportunities and implementing initiatives to improve operational efficiencies. The presentation also includes industry overview and comparative analysis of the healthcare sector in India and Gujarat.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.